Celastrol from Tripterygium wilfordii protects diabetic rats against cognitive decline by improving insulin sensitivity, glucose tolerance, and reducing inflammation in the brain. Celastrol also promotes the synthesis of synaptic proteins, enhancing cognitive function.
Triptonide from Tripterygium wilfordii is a potent anti-ovarian cancer agent, inducing apoptosis and autophagy through the p38/p53 pathway. It has better efficacy than platinum agents, offering a promising new treatment option.
Celastrol-chitosan conjugate Cel-CS1K showed promise as an antiobesity drug with higher drug loading, good solubility, and reduced toxicity compared to free Cel. It effectively reduced body weight, improved metabolic markers, and regulated adipose-related genes in obese mice, offering a potential therapeutic strategy for obese humans.
Bergenin helps prevent premature ovarian failure caused by Tripterygium wilfordii in mice by reducing oxidative stress and preventing ovarian cell apoptosis. Could improve clinical use of TW preparations for autoimmune diseases.
Triptolide (TPL) from a Chinese herb shows promise for fighting cancer, but its mechanism is unclear and its toxicity limits use. Research is underway to better understand how TPL works and improve its clinical application for treating tumors.
Celastrol from Tripterygium wilfordii roots reduces airway inflammation and hyperresponsiveness in obese asthma by balancing M1/M2 alveolar macrophage polarization, possibly through the PI3K/AKT pathway. This could lead to new therapeutic options for obese asthma.
"SB and CEL inhibit DNA repair, induce apoptosis, and modulate autophagy in glioblastoma cells, showing potential as effective treatments. Important for developing new therapies for this aggressive brain cancer."
Study on Demethylzeylasteral (T-96) from Tripterygium wilfordii Hook F shows its potential for treating allergic asthma by modulating immune response. Important for future asthma treatments.
Celastrol protects neurons by improving mitochondrial function and blocking cell death pathways in ICH-induced secondary brain injury. Targeting EPAC-1 with celastrol shows promise as a therapeutic strategy.
Study clones and analyzes CoGPPS in Cornus, important for biosynthesis of medicinal CIGs. CoGPPS specifically expressed in fruits, potentially main source of CIGs. Essential for future production studies.
Researchers investigated the effects of triptolide on cardiac remodeling, a common feature in heart diseases. They found that triptolide can inhibit cardiac hypertrophy and fibrosis, suggesting its potential as a treatment option.
Triptolide, a component of "Tripterygium Wilfordii," has potential as a cancer therapy. It induces cancer cell death, targets various proteins and pathways, enhances the effectiveness of chemotherapeutics, and can be combined with other therapies to combat toxicities. Exciting advancements are expected in the near future.
Triptolide, an active compound from Tripterygium wilfordii, kills gastric cancer cells by increasing reactive oxygen species (ROS) levels. It targets peroxiredoxins-2 (PRDX2) to inhibit its antioxidant activity, leading to apoptosis. PRDX2 could be a potential therapeutic target for anti-gastric cancer agents.
Triptolide (TPL) from Tripterygium wilfordii inhibits colorectal cancer (CRC) cell growth and invasion. It promotes cell death and reduces the levels of MMP-2 and MMP-9. The mechanism involves inhibition of Nrf2 signaling.
Triptolide, a compound from Tripterygium wilfordii Hook F, enhances the effectiveness of paclitaxel in treating paclitaxel-resistant lung cancer cells by inhibiting the HNF1A/SHH/ABCB1 pathway. This study suggests potential use of triptolide as a therapy for patients with paclitaxel resistance.
Triptolide, an ingredient in traditional Chinese medicine, shows promise in treating ankylosing spondylitis (AS) by regulating the long non-coding RNA NONHSAT227927.1. This study demonstrates that Triptolide reduces inflammation in AS-fibroblast-like synoviocytes (FLSs) and inhibits the JAK2/STAT3 pathway via NONHSAT227927.1.
TwHF reduces proteinuria in patients with diabetic kidney disease (DKD), but its impact on renal outcomes remains unknown. This study examines the effects of TwHF on renal outcomes in DKD patients.
Triptolide, derived from traditional Chinese medicine, reduces nerve damage after brain injury by inhibiting the NogoA/NgR/ROCK pathway and enhancing synaptic function. Promising treatment option for cerebral ischemia-reperfusion injury.
Traditional Chinese herb (TwHF) has shown promising results in the treatment of psoriasis, reducing symptoms and improving quality of life. It achieves this by modulating inflammatory cytokines and immune cells. However, it may also cause adverse reactions. TwHF could be considered as an alternative therapy for psoriasis.
Scientists investigated the effectiveness of Tripterygium wilfordii Hook F extract for treating rheumatoid arthritis. This herbal treatment has been used since the 1960s and could offer potential relief for RA symptoms.
Celastrol, a compound from Tripterygium wilfordii Hook. f., can treat diseases. This study shows it induces ovarian insufficiency and cell apoptosis by binding to high mobility group box 1. Important for assessing celastrol's safety in female patients.
Demethylzeylasteral, a natural compound derived from Tripterygium wilfordii, has shown potent anti-colon cancer activity. This study identifies S100A11 as a target protein and NF-κB as a regulator of S100A11 expression, highlighting the potential of demethylzeylasteral for anti-tumor therapy.
The Zhuidu Formula (ZDF) contains triptolide, cinobufagin, and paclitaxel, derived from natural sources. Studies have shown that these compounds have anti-tumor properties by affecting DNA synthesis, promoting tumor cell death, and disrupting tubulin balance. However, their role in inhibiting triple-negative breast cancer (TNBC) metastasis remains unclear. Understanding this mechanism could lead to new treatments for TNBC.